Unity Biotechnology (NASDAQ:UBX) PT Set at $14.00 by Morgan Stanley

Unity Biotechnology (NASDAQ:UBX) has been given a $14.00 target price by equities researchers at Morgan Stanley in a note issued to investors on Monday, TipRanks reports. The firm presently has a “buy” rating on the stock. Morgan Stanley’s target price indicates a potential upside of 80.41% from the stock’s previous close.

Separately, Zacks Investment Research lowered Hess Midstream Partners from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $19.50.

Unity Biotechnology stock traded down $0.31 on Monday, hitting $7.76. 7,509 shares of the stock traded hands, compared to its average volume of 395,174. The stock has a market capitalization of $356.13 million, a price-to-earnings ratio of -3.06 and a beta of -0.24. The firm has a fifty day moving average of $8.58. Unity Biotechnology has a 1 year low of $7.30 and a 1 year high of $24.56.



Unity Biotechnology (NASDAQ:UBX) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.03. On average, sell-side analysts predict that Unity Biotechnology will post -1.91 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC increased its holdings in Unity Biotechnology by 18.2% in the 1st quarter. FMR LLC now owns 4,551,523 shares of the company’s stock worth $36,913,000 after buying an additional 700,500 shares in the last quarter. BlackRock Inc. increased its holdings in Unity Biotechnology by 441.2% in the 4th quarter. BlackRock Inc. now owns 1,850,882 shares of the company’s stock worth $30,095,000 after buying an additional 1,508,908 shares in the last quarter. Northern Trust Corp increased its holdings in Unity Biotechnology by 293.7% in the 4th quarter. Northern Trust Corp now owns 230,152 shares of the company’s stock worth $3,742,000 after buying an additional 171,696 shares in the last quarter. Geode Capital Management LLC increased its holdings in Unity Biotechnology by 151.0% in the 4th quarter. Geode Capital Management LLC now owns 145,488 shares of the company’s stock worth $2,365,000 after buying an additional 87,519 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Unity Biotechnology by 273.3% in the 4th quarter. Bank of New York Mellon Corp now owns 58,620 shares of the company’s stock worth $953,000 after buying an additional 42,915 shares in the last quarter. 38.21% of the stock is owned by hedge funds and other institutional investors.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.

See Also: What does earnings per share mean?

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.